Lei Ji1,2, Lei Cheng1,2, Xiuzhi Zhu2,3, Yu Gao1,2, Lei Fan4,5, Zhonghua Wang6,7,8. 1. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. 3. Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. 4. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. teddyfl@163.com. 5. Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. teddyfl@163.com. 6. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. zhonghuawang95@hotmail.com. 7. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. zhonghuawang95@hotmail.com. 8. Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. zhonghuawang95@hotmail.com.
Abstract
BACKGROUND: Liver metastasis is a significant adverse predictor of overall survival (OS) among breast cancer patients. The purpose of this study was to determine the risk and prognostic factors of breast cancer with liver metastases (BCLM). METHODS: Data on 311,573 breast cancer patients from the Surveillance, Epidemiology, and End Results (SEER) database and 1728 BCLM patients from Fudan University Shanghai Cancer Center (FUSCC) were included. Logistic regression was used to identify risk factors for liver metastasis. Cox proportional hazards regression model was adopted to determine independent prognostic factors in BCLM patients. RESULTS: Young age, invasive ductal carcinoma, higher pathological grade, and subtype of triple-negative and human epidermal growth factor receptor 2 positive (HER2+) were risk factors for developing liver metastasis. The median OS after liver metastasis was 20.0 months in the SEER database and 27.3 months in the FUSCC dataset. Molecular subtypes also played a critical role in the survival of BCLM patients. We observed that hormone receptor-positive (HR+)/HER2+ patients had the longest median OS (38.0 for SEER vs. 34.0 months for FUSCC), whereas triple-negative breast cancer had the shortest OS (9.0 vs. 15.6 months) in both SEER and FUSCC. According to the results from the FUSCC, the subtype of HR+/HER2+ (hazard ratio (HR) = 2.62; 95% confidence interval (CI) = 1.88-3.66; P < 0.001) and HR-/HER2+ (HR = 3.43; 95% CI = 2.28-5.15; P < 0.001) were associated with a significantly increased death risk in comparison with HR+/HER2- patients if these patients did not receive HER2-targeted therapy. For those who underwent HER2-targeted therapy, however, HR+/HER2+ subtype reduced death risk compared with HR+/HER2- subtype (HR = 0.74; 95% CI = 0.58-0.95; P < 0.001). CONCLUSIONS: Breast cancer patients at a high risk for developing liver metastasis deserve more attention during the follow-up. BCLM patients with HR+/HER2+ subtype displayed the longest median survival than HR+/HER2- and triple-negative patients due to the introduction of HER2-targeted therapy and therefore it should be recommended for HER2+ BCLM patients.
BACKGROUND:Liver metastasis is a significant adverse predictor of overall survival (OS) among breast cancerpatients. The purpose of this study was to determine the risk and prognostic factors of breast cancer with liver metastases (BCLM). METHODS: Data on 311,573 breast cancerpatients from the Surveillance, Epidemiology, and End Results (SEER) database and 1728 BCLM patients from Fudan University Shanghai Cancer Center (FUSCC) were included. Logistic regression was used to identify risk factors for liver metastasis. Cox proportional hazards regression model was adopted to determine independent prognostic factors in BCLM patients. RESULTS: Young age, invasive ductal carcinoma, higher pathological grade, and subtype of triple-negative and humanepidermal growth factor receptor 2 positive (HER2+) were risk factors for developing liver metastasis. The median OS after liver metastasis was 20.0 months in the SEER database and 27.3 months in the FUSCC dataset. Molecular subtypes also played a critical role in the survival of BCLM patients. We observed that hormone receptor-positive (HR+)/HER2+ patients had the longest median OS (38.0 for SEER vs. 34.0 months for FUSCC), whereas triple-negative breast cancer had the shortest OS (9.0 vs. 15.6 months) in both SEER and FUSCC. According to the results from the FUSCC, the subtype of HR+/HER2+ (hazard ratio (HR) = 2.62; 95% confidence interval (CI) = 1.88-3.66; P < 0.001) and HR-/HER2+ (HR = 3.43; 95% CI = 2.28-5.15; P < 0.001) were associated with a significantly increased death risk in comparison with HR+/HER2- patients if these patients did not receive HER2-targeted therapy. For those who underwent HER2-targeted therapy, however, HR+/HER2+ subtype reduced death risk compared with HR+/HER2- subtype (HR = 0.74; 95% CI = 0.58-0.95; P < 0.001). CONCLUSIONS:Breast cancerpatients at a high risk for developing liver metastasis deserve more attention during the follow-up. BCLM patients with HR+/HER2+ subtype displayed the longest median survival than HR+/HER2- and triple-negative patients due to the introduction of HER2-targeted therapy and therefore it should be recommended for HER2+ BCLM patients.
Authors: Siker Kimbung; Ida Johansson; Anna Danielsson; Srinivas Veerla; Suzanne Egyhazi Brage; Marianne Frostvik Stolt; Lambert Skoog; Lena Carlsson; Zakaria Einbeigi; Elisabet Lidbrink; Barbro Linderholm; Niklas Loman; Per-Olof Malmström; Martin Söderberg; Thomas M Walz; Mårten Fernö; Thomas Hatschek; Ingrid Hedenfalk Journal: Clin Cancer Res Date: 2015-08-14 Impact factor: 12.531
Authors: D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton Journal: N Engl J Med Date: 2001-03-15 Impact factor: 91.245
Authors: S C Lindgaard; C M Brinch; B K Jensen; H H Nørgaard; K L Hermann; S Theile; F O Larsen; B V Jensen; H Michelsen; K M Nelausen; V H Holm; L Ekblad; Peter G Soerensen; D L Nielsen Journal: Breast Date: 2018-12-05 Impact factor: 4.380
Authors: Gunter von Minckwitz; Andreas du Bois; Marcus Schmidt; Nicolai Maass; Tanja Cufer; Felix E de Jongh; Eduard Maartense; Christoph Zielinski; Manfred Kaufmann; Wolfgang Bauer; Klaus H Baumann; Michael R Clemens; Ralph Duerr; Christoph Uleer; Michael Andersson; Robert C Stein; Valentina Nekljudova; Sibylle Loibl Journal: J Clin Oncol Date: 2009-03-16 Impact factor: 44.544
Authors: Rebecca Dent; Wedad M Hanna; Maureen Trudeau; Ellen Rawlinson; Ping Sun; Steven A Narod Journal: Breast Cancer Res Treat Date: 2008-06-10 Impact factor: 4.872
Authors: Cameron N Johnstone; Andrew D Pattison; Paul F Harrison; David R Powell; Peter Lock; Matthias Ernst; Robin L Anderson; Traude H Beilharz Journal: Int J Cancer Date: 2020-02-24 Impact factor: 7.396